The association between breast cancer risk and genetic variants of fibroblast growth factor receptor 2 (FGFR2) has been identified and repeatedly confirmed; however, the mechanism underlying FGFR2 in breast tumorigenesis remains obscure. Given that breast tumorigenesis is particularly related to DNA double-strand-break-repair (DSBR), we examined the hypothesis that FGFR2 is involved in DSBR. Our results show that expression of Mre11, a vital exonuclease in DSBR, is downregulated by FGFR2, which is further linked to decreased DSBR. Analysis of the Mre11 promoter revealed that POU1F1 mediates FGFR2-induced Mre11 downregulation. Furthermore, ERK, downstream of FGFR2, directly interacts with and phosphorylates POU1F1, increasing POU1F1 binding capacity to the Mre11 promoter and repressing Mre11 expression, which consequently affects DSBR and sensitizes breast cancer cells to chemotherapeutic treatments. The importance of the FGFR2-Mre11-DSBR link in cancer progression is suggested by the finding that genotypes of FGFR2 and Mre11 are associated with survival of breast cancer patients and that FGFR2 expression correlates with cancer prognosis specifically in patients receiving chemotherapy. This study yields important insight into the role of FGFR2 in breast tumorigenesis and may facilitate development of a useful therapeutic approach for breast cancer.
Introduction
Fibroblast growth factor receptor 2 (FGFR2) is a member of the receptor tyrosine kinase gene superfamily, and binding of ligand to FGFR2 induces its homodimerization and autophosphorylation. Activated FGFR2 recruits downstream effector or adaptor proteins, including RAS/MAPK, PI3 K/AKT, phospholipase C γ and STAT, and initiates signal transduction (1) . Somatic mutation of FGFR2 and alteration of FGFR2-associated signaling pathways are involved in various processes during tumorigenesis, including cell proliferation, invasiveness, motility and angiogenesis (1, 2) . FGFR2 has attracted considerable attention because a single-nucleotide polymorphism (SNP), rs2981582, in intron 2 was identified as the SNP most significantly associated with breast cancer susceptibility in a genome-wide association study (GWAS) (3) . Since then, rs2981582 and other FGFR2 SNPs have been examined for associations with breast cancer and, although not totally homogeneous in different ethnic groups or subtypes, the association between breast cancer risk and FGFR2 SNPs has been replicated and confirmed (4) (5) (6) . These associations have been suggested to be attributable to allele-specific differences of rs2981582 and other SNPs that not only affect FGFR2 mRNA level by altering the binding of transcription regulators, such as FOXA1 and E2F, in an ERα-dependent manner (7, 8) , but also involve in the increase of FGFR2 signaling activity (9) . These genetic findings support a causal role for FGFR2 in breast cancer development. However, an even more important issue remains to be explored, namely why FGFR2 is of particular importance in the development of breast cancer. Given that somatic abnormality of FGFR2 has been implicated in the oncogenic pathways of various cancer types (10) (11) (12) , it is interesting that FGFR2 SNPs have not been found to be risk alleles for cancers other than breast cancer. The aim of the present study was thus to address the issue of tissue specificity by examining whether FGFR2 is linked to DNA double-strand break repair (DSBR), the repair mechanism particularly important in breast cancer development (13) (14) (15) (16) . We started with the demonstration that FGFR2 impaired homologous recombination repair (HRR) and non-homologous end joining (NHEJ), both of which are involved in repair of DNA double-strand breaks (DSBs) (17, 18) . Subsequent screening of the expression of genes functionally related to DSBR and examination of possible signaling pathways downstream of FGFR2 revealed a novel mechanism in which FGFR2, acting via the MEK/ERK/ POU1F1 pathway, decreases DSBR by downregulating transcription of the gene encoding Mre11, an exonuclease that not only recruits to DSB sites to initiate DNA damage response (DDR) but also harbors 3′-5′ exonuclease activity to facilitate DSBR (19) (20) (21) . This study yields important insight into the breast tumorigenic role of FGFR2 and may help in the development of a useful therapeutic approach for breast cancer.
Results

FGFR2 decreases DSBR by reducing Mre11 expression
DNA damage response and DNA repair are impaired in cancers. Because breast cancer development is highly associated with DSBR (13-16), we hypothesized that FGFR2 plays a role in breast tumorigenesis by affecting DSBR. Two principal pathways, HRR and NHEJ, operate in DSBR (18, 22) . To assay HRR, we used U2OS-DR-GFP cells, which are U2OS cells with a chromosomally integrated HRR substrate, i.e. the DR-GFP reporter plasmid bearing a rare endonuclease I-Sce I (SceGFP) and a partial GFP (iGFP) (Supplementary Material, Fig. S1A ). Subsequent transfection with pSce (an I-Sce I-expressing plasmid) leads to cleavage of SceGFP, allowing quantification of HRR capacity by sorting the repaired GFP-positive cells by fluorescence-activated cell sorting (FACS) (23) . Using this HRR-specific assay, overexpression of FGFR2 or increased FGFR2 activity caused by binding of its ligand FGF7 significantly reduced HRR activity (Fig. 1A) . In contrast, transfection with the double mutant form of FGFR2 (Y657/659F), FGFR2 DM , which is a known FGFR2 kinase inactive mutant and interferes with signaling downstream of FGFR2 (24, 25) , allowed the cells to repair DSBs through HRR (Fig. 1A) .
To determine the effect of FGFR2 on NHEJ capacity, the HindIIIor EcoRI-linearized pGL2-control plasmid, which harbors the luciferase reporter gene, was transfected into MCF-7 human breast cancer cells (26) . The related overall (HindIII-digested) and precise (EcoRI-digested) NHEJ activities were evaluated by measuring luciferase activity (Supplementary Material, Fig. S1B ). Consistent with that observed for HRR, NHEJ capacity was significantly attenuated under conditions of FGFR2 overexpression or treatment with FGF7, and, in contrast, blocking downstream signaling using FGFR2 DM resulted in no impact on the repair capacity (Fig. 1B) .
The findings observed for HRR and NHEJ consistently lend support for a role of FGFR2 in DSBR. Considering that FGFR2 is a receptor tyrosine kinase and functions through activation of downstream signaling pathways, and that DSBR operates in the nucleus, we adopted a straightforward hypothesis that FGFR2-associated signaling may affect the expression of a specific DSBR gene(s) in the nucleus. We thus screened the relative expression of proteins that directly participate in both NHEJ and HRR (Fig. 1C) . Expression of Mre11, a vital exonuclease that facilitates DSBR in both NHEJ and HRR (19) (20) (21) , was reduced by overexpression of FGFR2; but other proteins were not affected (Fig. 1C) . To verify the involvement of Mre11 in FGFR2-associated DSBR, we examined the specificity of this association. Decreased Mre11 expression and decreased HRR capacity were specifically seen in cells overexpressing FGFR2 but not genes encoding other members of the FGFR family (FGFR1, FGFR3 and FGFR4; Fig. 1D and E). These findings showing specificity of the association between FGFR2 overexpression and decreased Mre11 expression and DSBR capacity suggested a causal relationship. In contrast, in the gastric carcinoma cell line, KATO III, in which FGFR2 is highly expressed (27) , siRNA-mediated knockdown of FGFR2 expression led to an increased Mre11 level (Supplementary Material, Fig. S1C Fig. S1D and S1E) consistently demonstrated an inverse relationship between FGFR2 and Mre11 expression, supporting the tumorigenic relevance of this association.
To obtain more evidence to support the causal association between FGFR2 and Mre11/DSBR, we tested whether the introduction of Mre11 could reverse the DSBR impairment caused by FGFR2 overexpression. Consistent with this expectation, both HRR and NHEJ activities were recovered when Mre11 and FGFR2 were co-transfected into MCF-7 cells, when compared with the activities in cells transfected with FGFR2 alone ( Fig. 1G ; Supplementary Material, Fig. S1F ). We therefore concluded that DSBR capacity, as decreased by FGFR2 overexpression, occurred by decreasing Mre11 expression.
In DSBR, Mre11 forms the MRN complex with Rad50 and NBS1 (19) ; in response to DNA DSBs, the MRN complex is recruited to the damaged site and activates ATM autophosphorylation at Ser1981. Subsequent H2AX phosphorylation (γ-H2AX) mediated by activated/autophosphorylated ATM facilitates the recruitment of other repair proteins, including the MRN complex, which initiates DSB resection to fix DSBs (29) . Because FGFR2 decreased Mre11 expression, it was meaningful to know whether the molecular mechanisms mediated by the MRN complex were affected. Thus, we evaluated MRN complex-mediated ATM and H2AX phosphorylation in FGFR2-overexpressing MCF-7 cells after DSBs were induced by ionizing radiation. At 30 min after ionizing radiation damage, both immediate MRN complexmediated ATM autophosphorylation (ATM pS1981) and γ-H2AX were reduced in FGFR2-overexpressing MCF-7 cells when compared with vector control (Cont) (Fig. 1H) . However, the effector role of the MRN complex in DSBR was altered upon FGFR2 overexpression because at 48 h after ionizing radiation, phosphorylation of both ATM and γ-H2AX were maintained owing to impaired clearance of DSB sites (Fig. 1H ).
FGFR2-induced inhibition of Mre11 expression is mediated by the transcription factor POU1F1
Immunoblotting and quantitative reverse transcription-PCR in different breast cancer cell lines consistently showed that both protein and mRNA levels of Mre11 were downregulated in the presence of both FGFR2 overexpression and treatment with FGF7 ( Fig. 2A and B; Supplementary Material, Fig. S2A and S2B ). To examine this hypothesis, the promoter region of Mre11 was cloned upstream of the luciferase reporter gene, and the promoter activity was assessed by measuring luciferase activity (30) . Deletion of specific regions of the Mre11 promoter indicated that the breast cancerrelated transcription factor, POU1F1 (31, 32) , may be a mediator of FGFR2-driven inhibition of Mre11 expression (Supplementary Material, Fig. S2D ). Indeed, knockdown of POU1F1 by siRNA or deletion of the POU1F1 binding site (Δ+52∼+58) in the Mre11 promoter significantly blocked the FGFR2-induced reduction of promoter activity ( Fig. 2C ) (32) . As expected, the FGFR2-dependent reduction in Mre11 expression was also restored by POU1F1 silencing ( Fig. 2D ; consistent results in different breast cell line in Supplementary Material, Fig. S2E ). To further evaluate whether Mre11 expression was regulated by POU1F1, we monitored Mre11 expression in the presence or absence of POU1F1. Overexpression of POU1F1 negatively regulated Mre11 at both the mRNA and protein levels ( Fig. 2E and F) and also attenuated HRR and NHEJ repair capacity ( Fig. 2G and H), whereas POU1F1 silencing reversed these effects. This indicates that Mre11 is transcriptionally downregulated by POU1F1, which is responsible for the FGFR2-mediated inhibition of Mre11 expression.
FGFR2 downregulates Mre11 expression and DSBR through MEK/ERK signaling
There are four main signaling pathways downstream of FGFR: RAS/MAPK, PI3 K/AKT, JNK and STAT (1). To explore how FGFR2 regulates Mre11 expression, we first used a phosphokinase array to screen for activation of these pathways. The elevation of phosphorylated forms of AKT and ERK showed that the PI3K/ AKT and MEK/ERK pathways were activated by FGFR2 overexpression in MCF-7 cells (Fig. 3A) . Moreover, treatment with kinase inhibitors indicated that a MEK inhibitor (U0126), but not PI3K inhibitor (LY294002), restored the FGFR2-inhibited Mre11 expression at both the mRNA and protein levels ( Homologous recombination repair (HRR) capacity (G) and non-homologous end joining (NHEJ) activity (H) were both reduced by POU1F1 overexpression and rescued by knock-down of POU1F1. All vector and vehicle control in the above experiments are presented as Cont. The quantification values were normalized to Cont, and are presented as the mean ± SD, n = 6. *P < 0.05 for the difference between each indicated groups and Cont.
with U0126 and co-transfection with the dominant-negative form of MEK1 (MEK1 DN ) both restored the inhibited NHEJ activity caused by overexpression of FGFR2 (Supplementary Material, Fig. S3B ). Thus, FGFR2-suppressed Mre11 expression and DSBR capacity were mediated by activation of MEK/ERK signaling.
POU1F1 phosphorylation, which is directly mediated by ERK, regulates Mre11 expression
Thus far our findings demonstrated that Mre11 is regulated not only by FGFR2-downstream MEK/ERK signaling ( Fig. 3 ) but also by POU1F1 (Fig. 2) . Thus, we investigated the potential link between POU1F1 and MEK/ERK signaling. We carried out chromatin immunoprecipitation with an antibody against POU1F1 to trap the POU1F1-associated transcription complex. We then used quantitative PCR to examine the amount of POU1F1-bound Mre11 promoter. The amount of POU1F1 bound to the Mre11 promoter was elevated upon FGFR2 overexpression but was reduced upon treatment with the MEK inhibitor (U0126) (Fig. 4A) ; this finding linked FGFR2, MEK/ERK, POU1F1 and Mre11 expression. To clarify the mechanism underlying this link, the interaction between ERK and POU1F1 was characterized. A co-immunoprecipitation assay showed that POU1F1 was physically associated with ERK (Supplementary Material, Fig. S4A ), and the interaction between endogenous POU1F1 and ERK was enhanced in response to FGF7 treatment (Fig. 4B ). To further confirm that POU1F1 can be phosphorylated by MEK/ERK signaling, we immunoprecipitated POU1F1 and immunoblotted with the specific antibody against phospho-MAPK substrate proteins having the consensus sequence, threonine or serine followed by a proline residue. The results showed that POU1F1 was the substrate of MAPK/ERK, and, more importantly, that FGFR2 overexpression facilitated MEK/ERK-mediated POU1F1 phosphorylation (Fig. 4C) . Because that activated phospho-ERK is capable of shuttling from cytoplasm to nucleus, further study to comprehensively examine how and where ERK phosphorylates POU1F1 and facilitates the binding of POU1F1 to Mre11 promoter is needed. The findings in Figure 4B and C suggested that ERK may phosphorylate POU1F1. This was confirmed by an in vitro kinase assay, which showed that the wild-type POU1F1-GST fusion protein was directly phosphorylated by recombinant-activated ERK (Fig. 4D) . This activity was inhibited by the ERK inhibitor, FR180204. Furthermore, of two conserved ERK phosphorylation sites on POU1F1, Thr75 and Ser126 (upper panel of Fig. 4D ), Thr75 was used predominantly; a mutant in which Thr75 was substituted with Ala (POU1F1 T75A , a phospho-dead mutant of POU1F1) was resistant to ERK-mediated phosphorylation (lower panel of Fig. 4D ). In contrast, after the same substitution of Ser126 (POU1F1 S126A ), the phosphorylation of POU1F1 by ERK remained the same (Fig. 4D) . We therefore generated a specific antibody against phosphorylated Thr75 of POU1F1 and used it to demonstrate that FGFR2 stimulated phosphorylation of Thr75 in vivo, which was blocked by the MEK inhibitor (U0126) but not by the PI3 K inhibitor (LY294002) (Fig. 4E) . Consistent with the POU1F1 phosphorylation level, Mre11 expression was not reduced by POU1F1 T75A but was repressed by the phosphomimetic mutant, POU1F1 T75E , in different breast cancer cell lines ( Fig. 4F ; Supplementary Material, Fig. S4B and S4C ). Transfection with a plasmid encoding POU1F1 S126A or POU1F1 S126E also showed no effect on Mre11 expression (Fig. 4F) . These results together suggested that FGFR2-reduced Mre11 expression is mediated by MEK/ERK-stimulated POU1F1 phosphorylation, which regulates the binding capacity of POU1F1 to the Mre11 promoter.
FGFR2-Mre11 pathway regulates breast cancer susceptibility and survival and sensitizes breast cancer cells to chemotherapeutic agents
As the mechanism of the FGFR2-Mre11 pathway was clarified and confirmed in our breast cancer cell model, we next addressed the issue of its translational relevance to breast tumorigenesis. If the genes of this identified pathway are associated with breast cancer development via the identified mechanism involving the regulation of DSBR, the relationship between cancer development and genotypes of FGFR2 or genes involved in FGFR2 signaling would be expected to be even more significant in a subset of women carrying high-risk genotypes of Mre11. The SNP in intron 2 of FGFR2, rs2981584, which is located in the same linkage disequilibrium block of the known breast cancer risk-related SNP, rs2981582, , POU1F1 S126A and POU1F1 S126E did not reduce Mre11 expression. All vector and vehicle control in the above experiments are presented as Cont.
was chosen to reflect polymorphic status of FGFR2 owing to its significance in association with breast cancer risk. The genotypic variant, rs11020803, on the other hand, was chosen to reflect the polymorphic status of Mre11, because it is located in the promoter region of Mre11, which has the potential to be associated with the Mre11 expression level. Consistent with the idea that FGFR2 and Mre11 interact to affect breast cancer risk, the breast cancer risk conferred by carrying the at-risk genotypes of FGFR2 was modified by rs11020803 and was particularly significant in women carrying the specific genotype of Mre11 (Fig. 5A) . Similarly, if the joint effect of the entire signaling pathway was considered, the breast cancer risk associated with harboring one additional at-risk genotype of FGFR2-ERK-POU1F1 was seen only in women carrying the at-risk genotype rs11020803 (Fig. 5A) . Because the extent of DSBs is associated with tumor grade or cancer stage (33) , the involvement of FGFR2 in DSBR suggests a role for FGFR2 in breast cancer progression. Based on the mechanism identified in the present study, we purposely selected the SNP rs1219643 to reflect the polymorphic status of FGFR2, the variant allele (T allele) of which was demonstrated to lead to increased expression of the reporter gene (Fig. 5B) , presumably resulting in decreased DSBR and higher DSB formation. Consistent with this speculation, breast cancer patients carrying the variant allele rs1219643 were associated with poorer diseasefree survival (Fig. 5C ). More interestingly, as seen in the case of breast cancer development (Fig. 5A) , the interaction between FGFR2 and Mre11 was associated with breast cancer progression, as shown by the finding that the association between FGFR2 and disease-free survival was significantly modified by Mre11 rs11020803 and was only seen in patients carrying at-risk genotypes of Mre11 (left panel of Fig. 5D ) but not in others (right panel of Fig. 5D ).
The involvement of FGFR2 in response to therapy is of particular interest and importance. Overexpression of FGFR2 reduces DSBR, which may increase sensitivity to chemotherapeutic agents that cause DSB formation. The MTT assay was performed to examine the drug sensitivity of breast cancer cells. After treatment with doxorubicin and etoposide (both are chemotherapeutic agents resulting in DSBs and are commonly used in the clinic), substantially lower viability was observed in FGFR2-overexpressing MCF-7 cells when compared with cells infected with the vector control (Fig. 6A) . Introduction of Mre11 into the FGFR2-overexpressing cells restored viability, supporting our earlier result showing that Mre11 acts downstream of FGFR2-attenuated DSBR. The translational relevance of this finding can be demonstrated based on publically available data from two independent breast cancer patient cohorts of large sample size (28, 34) . In the subgroup of patients who received chemotherapy (mostly doxorubicin and etoposide, which cause DSBs), high expression of FGFR2 in tumorssupposedly resulting in reduced DSBR and greater sensitivity to chemotherapy-was significantly associated with better survival (left panels of Supplementary Material, Fig. S5A and S5B ); in contrast, no such association was detected in patients who did not receive chemotherapy (right panels of Supplementary Material, Fig. S5A and S5B ).
Discussion
The move from candidate gene association studies to GWASs has made it possible to explore the etiological contributions of genetic variants throughout the genome without relying on an a priori hypothesis. As a result, many novel loci have been identified. However, with only a very few notable exceptions, the number of detected causal variants directly responsible for the associations identified in individual GWASs remains small, and most loci identified by GWASs require further fine-mapping (35, 36) , which usually is time consuming and laborious. To our knowledge, since 2007 until recently, comprehensive fine-scale mapping of the FGFR2 locus using dense SNP genotyping from populations of European, Asian and African-American ancestry within the International Breast Cancer Association Consortium has been just completed (8) . In the face of skepticism about the value of genetic information from GWASs for finding effective preventions and therapies, our study demonstrates that disease genetics can be translated into potential prevention and treatment strategies. Starting from the clue suggested by GWASs, we demonstrated a novel signaling mechanism, in which FGFR2 inhibits DNA DSBR. In this proposed pathway, FGFR2 overexpression triggers downstream MEK/ERK signaling, and activated ERK directly interacts with and phosphorylates POU1F1 at Thr75, which represses Mre11 transcription through binding to the Mre11 promoter (Fig. 6B) . Reduced expression of Mre11 in turn decreases Mre11-dependent HRR and NHEJ repair capacity, which not only leads to increased accumulation of DNA DSBs (Fig. 1H) , subsequently contributing to tumor formation (Fig. 5A) and progression ( Fig. 5C and D) , but also sensitizes breast cancer cells to chemotherapeutic drugs (Fig. 6A) . These findings exemplify how GWASs contribute to understanding tumorigenesis and developing therapeutic approaches.
As our understanding of tumorigenesis has been extended from single-gene mechanisms to multigenic or etiological pathway-wide networks, the consideration of whether there is a causal link between a putative cancer-associated gene and tumor development might be extended to entire tumorigenic networks. This was the rationale we used while attempting to link FGFR2 and DSBR. The importance of DSBR during breast tumorigenesis has been unambiguously demonstrated by the identification of familial breast cancer susceptibility genes, including BRCA1 and BRCA2, which are involved in repair DNA DSBs (16, 35, 37) . Furthermore, peripheral blood mononuclear cells from breast cancer patients show lower DSBR capacity in vivo and in vitro than those from healthy women (15, 37) . The contribution of DSBR to breast cancer development is also supported by evidence at the level of somatic abnormalities, and on the basis of genome-wide detection of DSBs breast cancer progression has been shown to be driven by DSB-initiated chromosome instability (18, 37, 38) . Thus, the participation of FGFR2 signaling in DSBR provides support for a unique role of FGFR2 in breast cancer development. Furthermore, in light of the fact that 15-40% of women carry the high-risk genotypes of FGFR2 associated with its increased expression (8) and that Mre11 plays an essential role in FGFR2-associated DSBR (Fig. 1) , a comprehensive study of all cancer patients with respect to the potential FGFR2-Mre11 link would be of particular translational relevance.
In the present study, we compared the effects of different FGFRs on Mre11 expression and DSBR. In breast cancer cells, FGFR2-attenuated Mre11 expression was quite specific and, although all FGFRs triggered activation of MAPK/ERK signaling detected by ERK phosphorylation (Fig. 1D) , FGFR2 was the only one responsible for the regulation of Mre11 and DSBR capacity (Fig. 1E) . This specificity is consistent with the recent GWAS of FGFR family members (39) and may be explained by the existence of an undefined protein(s) that participates in FGFR2-regulated Mre11 expression and interacts with FGFR2 to preferentially trigger specific downstream signaling. The identification of these proteins may lead to the development of possible means to intervene in this tumorigenic mechanism.
We found that breast cancer cells with FGFR2 overexpression showed defective DNA DSBR, thus sensitizing them to DSB-forming drugs such as doxorubicin and etoposide (Fig. 6A) . This implies that specific breast cancer cells may possess a limited repertoire of DNA repair mechanisms, providing a unique opportunity to specifically kill tumor cells using a treatment that can exacerbate this weakness. This possibility provides a partial explanation for the consistent findings seen in breast cancer patients that high expression of FGFR2 is associated with better prognosis in the particular subgroup of patients who received chemotherapy (Supplementary Material, Fig. S5 ). Furthermore, it is suggested that FGFR2 confers the effect on breast cancer susceptibility particularly in ER-positive breast tumors (7, 8, 40, 41) , and importantly, comprehensive analyses have sorted out that alteration of FGFR2 signaling can be caused by altered activity of ER-associated network, explaining why FGFR2 plays a highly dominant role in ER-positive breast cancer (41) . Given this, the present study aimed to explore and showed functional impacts downstream of upregulated FGFR2. Our findings may partially explain the heterogeneity of luminal-type breast cancer commonly seen in clinic, in which approximately one-third of the luminal-type/ ER-positive cancers are poorly responsive to endocrine therapies and more sensitive to chemotherapy, suggesting non-uniform tumor cell characteristics of this subtype (42) . Due to that the allele-specific upregulation of FGFR2 is in an ER-dependent manner (7, 8) , not all patients with the same ER status manifest the same cancer progression or response to hormone therapy. More importantly, this study suggests that FGFR2 expression may be a potential biomarker for selecting a suitable subgroup of breast cancer patients to receive chemotherapy or to determine the optimal chemotherapeutic dose. Interestingly, the ability of FGFR2 to elicit a DSBR defect raises the possibility that the synthetic lethality observed in triple-negative or BRCA-mutant breast cancer cells (37, 43) , both of which are characterized by reduced DSBR, can be applied to breast tumors overexpressing FGFR2. Our preliminary result that FGFR2-overexpressing breast cancer cells are more sensitive to ABT-888, a PARP inhibitor, is consistent with this possibility (Supplementary Material, Fig. S6 ). For cancer cells with reduced DSBR, such as BRCA-mutant cells or, as suggested by the present study, FGFR2-overexpressing breast cancer cells, treatment with an inhibitor of PARP, a critical enzyme responsible for single-strand break repair, results in DSB accumulation owing to frequent replication of tumor cells carrying single-strand breaks and subsequent greater sensitivity to PARP inhibition. Consistent with the FGFR2-Mre11-DSBR link we identified, deficiency of the Mre11 exonuclease has been shown to sensitize colorectal cancer cells to PARP inhibition (44) . Thus, the possibility of exploiting synthetic lethality as an alternative therapy for specific breast cancers with FGFR2 overexpression is intriguing and is a subject of our ongoing investigation.
Materials and Methods
Cell culture and reagents
The human breast cell line MCF-7 (ATCC cat. No. HTB-22) and T-47D (ATCC cat. No. HTB-133) were cultured in DMEM containing 10% FBS and RPMI1640 containing 10%FBS, respectively. The human gastric cancer cell line KATO III (ATCC cat. No. HTB-103) was cultured in RPMI1640 supplemented with 20% FBS. Human osteosarcoma U2OS cells containing the pDR-GFP reporter (U2OS-DR-GFP) were cultured in McCoy's 5A with 10% FBS and 1 μg/ml puromycin (Sigma). MEK inhibitor U0126, ERK inhibitor FR180204, PI3K inhibitor LY294002 and DSBproducing agents doxorubicin and etoposide were obtained from Sigma. PARP inhibitor ABT-888 was purchased from Selleckchem. Transfection was carried out using Lipofectamine2000 (Invitrogen).
Plasmids and siRNAs
Human FGFR2 was inserted into the pcDNA3 cassette (Invitrogen) with a Flag-tag at its C-terminus. FGFR1, FGFR3 and FGFR4 clones were purchased from Origene and subcloned into the Flag tagcontaining pcDNA3 vector ( pcDNA3-3 × Flag). Human POU1F1 was cloned into pEF/Myc/Cyto (Invitrogen). Plasmids pDR-GFP and pSce were provided courtesy of Dr Sheau-Yann Shieh (Institute of Biomedical Sciences, Academia Sinica). pGL2-control and pGL3-basic luciferase reporter vectors were purchased from Promega. For recombinant protein production, POU1F1 was cloned into pGEX-4T1 (Addgene). All mutant constructs were generated using the QuickChange Site-Directed Mutagenesis kit (Stratagene). The siRNA target sequences were: FGFR2, 5′-TGAAGAAC ACGACCAAGAAGC-3′; POU1F1, 5′-CTCTGCCTCTGATAATGCA-3′; control (random), 5′-AAGTCAATATGCGACTGATGG-3′.
HRR assay and flow cytometry
For the HRR assay (23, 45) , in brief, U2OS-DR-GFP cells were cotransfected with pSce (2 μg) and the gene-expressing plasmids (4 μg of an individual plasmid in a 60-mm tissue culture dish) or siRNA indicated in each figures (empty vector or scrambled siRNA as control). For FGF7 treatment, the cells were co-transfected with pSce and empty vector, and then medium was replaced with FGF7-containing culture medium. Transfection with pcDNA3-3 × Flag empty vector (6 μg) only (without pSce) in the cells was used as the GFP negative control. At 2 days posttransfection, the cells were trypsinized to yield individual cells, and the percentage of GFP-positive cells was quantified by FACS on a Becton Dickinson FACScan.
In vitro kinase assay
The ERK in vitro kinase assay was performed as described (46) . Human recombinant ERK2 (50 ng; Millipore) and recombinant GST-POU1F1, GST-POU1F1 T75A or GST-POU1F1 S126A (300 ng) were incubated in 20 μl of kinase buffer [50 m Tris-HCl ( pH 7.5), 10 m MgCl 2 , 1 m EGTA, 2 m DTT] supplemented with or without 100 μ ATP or FR180204 at 30°C for 4 h, and the reaction was terminated by the addition of 3 × Laemmli SDS sample buffer. The proteins were resolved by SDS-PAGE followed by immunoblotting.
RNA extraction and quantitative reverse transcription-PCR
Total RNA from cell lysates was isolated with TRIZOL (Invitrogen). A total of 4 μg of RNA per 20-μl reaction was reverse transcribed with the SuperScriptTM III reverse transcriptase kit (Invitrogen). Quantitative PCR was performed using Power SYBR Green PCR Master Mix (Life Technologies, Inc., Gaithersburg, MD) and the Applied Biosystems 7500 system. The primers pairs were: 5′-GAAGGTGAAGGTCGGAGT-3′ and 5′-GAAGATGGT GATGGGATTTC-3′ for GAPDH; 5′-CCAGAGAAGCCTCTTGTACG-3′ and 5′-TTCCACCTCTTCGACCTCTTC-3′ for Mre11.
Promoter assay
The Mre11 promoter region was defined by the EPD promoter database (30) . Transcription factor binding sites were predicted with TESS (32) . For the promoter assay, the partial fragment of the Mre11 promoter (nt −500 to +250) was cloned into the pGL3-basic Luciferase reporter vector. For POU1F1 binding-site analysis, the predicted binding region (nt +52 to +58) was deleted.
The promoter-bearing plasmid (0.2 μg/well in a 24-well plate) and the pRL-TK Renilla Luciferase control plasmid were cotransfected with the protein-expressing plasmid or siRNA as indicated in the figures, and cells were collected 2 days after transfection for measurement of luciferase activity. Relative luminescence units (RLUs) were calculated following the manufacturer's instructions.
NHEJ assay
The plasmid-based DNA end-joining assay was performed as described (26) . Briefly, the linearized pGL2-control plasmid was confirmed by agarose gel electrophoresis, and the DNA was extracted with the QIAquick Gel Extraction kit (Qiagen). MCF-7 cells were first transfected with a plasmid encoding FGFR2, FGFR2 DN , POU1F1, si-POU1F1 or control vector in a 60-mm tissue culture dish. After 24 h, the cells were reseeded onto 24-well plates. At 24 h after reseeding, the linearized or uncut plasmid (0.4 μg/well in a 24-well plate) was transfected into cells with 0.02 μg pRL-TK as an internal control. At 24 h after the final transfection, the cells were collected, and luciferase activity was measured with the Dual-Luciferase assay system (Promega).
Phospho-kinase array
Two days after transfection with pcDNA3-3 × Flag or pcDNA3-3 × Flag-FGFR2 (3 μg in a 60-mm tissue culture dish), MCF-7 cells were analyzed using a human phospho-kinase array following the manufacturer's manual (ARY003B; R&D).
Immunoblotting and immunoprecipitation
To detect MRN complex-mediated ATM and H2AX phosphorylation, the FGFR2-expressing clone and control clone were generated by pLX301-3 × Flag-lentiviral infection of MCF-7 cells (National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan). Puromycin (1 μg/ml) screening of infected cells was performed 2 days post-infection. After 2 weeks of selection, cells were preseeded in 60-mm tissue culture dishes and DSBs were induced by ionizing radiation (8 Gy). Cell lysates were collected at 30 min and 48 h after ionizing radiation damage for histone protein extraction. Total protein extraction, histone protein extraction, immunoprecipitation and immunoblotting were performed as described (26, 47, 48) . Protein was quantified using the Bradford method (Bio-Rad). Primary antibodies were used against the following proteins. From Bethyl: ATR; from Calbiochem: BRCA1; from Cell Signaling: Chk1, p-AKT, p53, p-ERK1/2, phospho-(Thr)MAPK/ CDK substrate; from Epitomics: ATM pS1981; from GeneTex: Mre11, CtIP, FGFR2, PARP1, Rad50, WRN, AKT; from Millipore: ERK1/2; from Novus: ATM, NBS1; from Sigma: Flag, Myc, Tubulin; from Santa Cruz Biotechnology: Chk2, POU1F1; and from Upstate: histone H2AX pS139. To generate the antibody against phosphoThr75 POU1F1, keyhole limpet hemocyanin-conjugated POU1F1 phosphopeptide (STYGVMAGSLpTPC) derived from residues 65-77 was used for antiserum production in rabbits by GeneTex (Taiwan). Bound primary antibodies were detected using horseradish peroxidase-conjugated goat anti-mouse IgG or horseradish peroxidase-conjugated anti-rabbit IgG (Jackson Immunoresearch, West Grove, PA, USA) and chemiluminescent reagents (Millipore, Temecula, CA, USA). Quantification of band intensities was determined by ImageJ (NIH).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed using the EZMagna ChIP kit (Millipore). Anti-POU1F1 (Santa Cruz Biotechnology) was used for immunoprecipitation. The primer pairs used for analyzing the POU1F1-bound Mre11 promoter were 5′-CGTGCGGTAGC CAATGAGA-3′ and 5′-CTGAATTCCGCGGGAGAGA-3′.
MTT assay
The drug sensitivity assay was performed using the MTT assay. The FGFR2-expressing clone and control clone were generated by pLX301-3 × Flag-lentiviral infection of MCF-7 cells (National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taiwan). Puromycin (1 μg/ml) screening of infected cells was performed 2 days post-infection, and after 2 weeks of selection, the cells were replated to 24-well plates (5 × 10 3 /well). Doxorubicin, etoposide or the PARP inhibitor ABT-888 was applied to cells 1 day after plating, and cells were then incubated for 24 h. Cell viability was evaluated by MTT assay 5 days after drug treatment.
Breast cancer patients, genotyping, clinical features and follow-up
The genotyping data for 837 incident breast cancer patients and 281 controls were examined to determine the associations of interest, including breast cancer risk and genotypic polymorphisms of FGFR2, Mre11, ERK and POU1F1. These cases were also used to determine whether there was an association between genotypic polymorphisms of FGFR2 and disease-free survival, and whether this association was modified by genotypic polymorphism of Mre11. Blood specimens were used to genotype specific SNP-tagged individual genes using a Sequenom iPLEX (Sequenom, Hamburg, Germany). Duplicate samples were used, and positive and negative controls were included on all plates; genotypes were autocalled by the software MassARRAY Typer version 3.4 (Sequenom) and confirmed by visual assessment of the data. Details of the clinical and pathological features were obtained from the tumor registries of our hospitals, the quality of which is well recognized (49) . This study used data generated by The Cancer Genome Atlas and the Molecular Taxonomy of Breast Cancer International Consortium. Hazard ratios and 95% confidence intervals were estimated using the Cox proportional hazard model, in which factors associated with breast cancer progression, e.g. the age of patients and stage of tumors, were adjusted.
